Choosing treatment for infantile hemangioma birthmarks in babies
Part of Cancer clinical trials.
This study looks at babies with a common birthmark called infantile hemangioma (made of blood vessels) to help doctors decide the best treatment or whether monitoring is enough. It involves a first evaluation and follow-up, but no new drugs or procedures are tested.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be diagnosed with an infantile hemangioma (a common type of birthmark) — either the usual kind or a type that grows very little.
- This must be your baby's first visit to the study doctor for this birthmark.
- Your baby should be under 24 months old at the time of the visit.
- Your baby must not have already received any treatment for the birthmark, like oral drugs, creams, laser, or surgery.
- Parents or guardians must be able to read and sign a consent form.
- The doctor must have enough information about the birthmark (location, size, etc.) to assess it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways of stopping propranolol in children with infantile hemangioma (a type of birthmark): stopping suddenly versus slowly reducing the dose. It aims to find out which method is safer and better at preventing the birthmark from growing back.
This study screens babies who have infantile hemangiomas (common birthmarks made of blood vessels) in certain areas of the lower body to see if they might have LUMBAR syndrome, a rare condition that can cause other health issues. The goal is to detect and address any related problems early.
This trial tests different starting doses of oral propranolol to see which works best and is safest for treating infantile hemangiomas that have ulcers (sores). It may help your child heal faster.
This trial tests a cream containing simvastatin, a cholesterol medicine, applied to infantile hemangiomas (strawberry birthmarks) in babies aged 3-6 months. It may help shrink the birthmark without needing stronger treatments.
This study compares three approaches—pulsed-dye laser, timolol (a medicated skin solution), or watch-and-wait—to see which works best to slow the growth of a hemangioma birthmark in young babies. It may help find a treatment that shrinks or controls the birthmark as early as possible.
This study compares two treatments for a common infant skin birthmark called hemangioma. One uses a special diode laser and the other uses a medicine called bleomycin, both aimed at shrinking or improving the birthmark.
Hear when a new Infantile Hemangioma (IH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.